To include your compound in the COVID-19 Resource Center, submit it here.

Merck discontinues HCV candidates MK-3682B and MK-3682C

Merck & Co. Inc. (NYSE:MRK) discontinued development of MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir), emptying its pipeline of candidates to treat HCV infection.

Read the full 220 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE